Boehringer Ingelheim highlights progress of immuno-oncology collaborations

In the last year, the firm has worked with the University of California at Los Angeles to develop a promising vaccine platform that can deliver a self-replicating RNA vaccine cargo to cancerous cells, helping the immune system to eliminate the cancer.

It has also partnered with Siamab Therapeutics to identify anticancer therapeutics that target tumour-associated carbohydrate antigens, while another collaboration with AbeXXa Biologics has been formed to identify new selective molecular targets for cancer from the thousands of proteins found inside tumour cells. Read more >>